| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.26 | 7e-13 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.24 | 8e-12 |
| mRNA | A-770041 | GDSC1000 | pan-cancer | AAC | 0.31 | 6e-10 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | 0.28 | 5e-09 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.19 | 1e-07 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | 0.18 | 4e-07 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | 0.18 | 5e-07 |
| mRNA | pluripotin | CTRPv2 | pan-cancer | AAC | 0.18 | 5e-07 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.18 | 1e-06 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.17 | 3e-06 |